High materiality7/10
Neurocrine price target raised to $200 from $155 at Truist
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Target raised to $200; current price $175.16; indicates upside potential.
- PT $200; price $175.16; Truist.
Key facts
- 01
Target: $200
- 02
Posted price: $175.16
- 03
Analyst firm: Truist Financial
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.